Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EMEA Projects Drug Applications Will Double In 2006

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency is unclear why applications are up, but notes that, unlike last year, there have been generic and biosimiliar applications.

You may also be interested in...

GSK Makes First Tykerb NDA Submission

GSK is seeking approval to market lapatinib for the treatment of advanced breast cancer in Herceptin-refractory patients.

Atripla Approved As First Once-Daily, Single-Tablet HIV Therapy

The Bristol/Gilead combination product will launch within seven business days.

Pfizer's Revatio Clears FDA For Pulmonary Arterial Hypertension

Revatio has the same active ingredient as Viagra, which the company markets for erectile dysfunction, but differs in dosing, pill color and pill shape. Pfizer will launch sildenafil for PAH in mid-July.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts